Limitations of current therapies to prevent thrombosis: a need for novel strategies

Area of Science:

• Cardiovascular pharmacology
• Thrombosis and hemostasis

Background:

• Anti-platelet drugs (aspirin, clopidogrel) prevent heart attacks and stroke but increase bleeding risk.
• Irreversible inhibition of COX1 and P2Y12 targets by aspirin and clopidogrel poses risks for emergency surgery.
• Clopidogrel efficacy is limited by CYP2C19 genotype, while prasugrel increases bleeding risk.

Purpose of the Study:

• To review current anti-platelet therapies and their limitations.
• To explore novel anti-platelet drug targets with potentially reduced bleeding risk.

Main Methods:

• Literature review of anti-platelet drug mechanisms and clinical trials.
• Analysis of pharmacogenomic data related to anti-platelet drug metabolism.
• Identification of emerging therapeutic targets for thrombosis prevention.

Main Results:

• Aspirin and clopidogrel have irreversible effects, increasing hemorrhage risk in surgical patients.
• CYP2C19 genetic variations affect clopidogrel efficacy; prasugrel offers benefits but with higher bleeding risk.
• Novel agents like reversible P2Y12 antagonists, PAR1 antagonists, and EP3 antagonists are under investigation.

Conclusions:

• There is a critical need for anti-platelet therapies with a better safety profile.
• EP3 receptor antagonists represent a promising strategy for selective thrombosis prevention with potentially lower bleeding risk.
• Targeting the EP3 receptor may decouple antithrombotic effects from hemostatic impairment in atherosclerotic disease.